8-K: Genprex Granted Nasdaq Listing Exception

Genprex, Inc. has received an exception from the Nasdaq Hearings Panel to continue listing on The Nasdaq Capital Market, subject to specific bid price requirements through December 7, 2026.

Summary

• Genprex, Inc. received notification from the Nasdaq Hearings Panel on July 29, 2026, granting an exception to continue listing on The Nasdaq Capital Market.
• The company must demonstrate compliance with the $1.00 Minimum Bid Price Requirement by July 29, 2026.
• Genprex must maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026.
• The Nasdaq Hearings Panel will retain jurisdiction over the company until December 7, 2026.
• The company implemented a 1-for-22 reverse stock split effective July 16, 2026, to help meet listing requirements.
• Failure to meet these terms could result in delisting, impacting the stock price, capital access, and investor confidence.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously negative development. While the company avoided immediate delisting, the strict conditions and the ongoing risk of non-compliance present significant challenges.

Positives

• The Nasdaq Hearings Panel granted an exception for continued listing on The Nasdaq Capital Market.
• The company has until December 7, 2026, to demonstrate compliance with the $1.00 Minimum Bid Price Requirement.
• A 1-for-22 reverse stock split was implemented on July 16, 2026, to address the bid price deficiency.

Negatives

• The company must demonstrate compliance with the $1.00 Minimum Bid Price Requirement by July 29, 2026.
• The company must maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026.
• There is no assurance that the company will be able to satisfy the terms of the exception or maintain compliance.
• The reverse stock split could negatively affect the stock price and liquidity.
• Delisting from Nasdaq could materially reduce the stock price, harm capital raising abilities, and reduce investor confidence.

Risks

• Failure to regain and maintain compliance with the $1.00 Minimum Bid Price Requirement by July 29, 2026.
• Failure to maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026.
• The possibility of becoming non-compliant with other Nasdaq listing rules during the exception period.
• The potential for the Nasdaq Hearings Panel to reconsider the exception based on future events.
• The reverse stock split may not result in regaining or maintaining compliance with the bid price requirement.
• Adverse effects on stock price, liquidity, and ability to raise capital if delisted from Nasdaq.
• Potential loss of investor confidence, suppliers, contractual counterparties, and employees if delisted.

Future Outlook

The company must demonstrate compliance with the $1.00 Minimum Bid Price Requirement by July 29, 2026, and maintain it through December 7, 2026. There is no guarantee of success in maintaining compliance or avoiding delisting. The company intends to take steps to evidence and regain compliance, including the recent reverse stock split.

Management Comments

• The Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events that occur that may affect our compliance with Nasdaq requirements.
• We intend to continue to monitor the closing bid price of our common stock and take definitive steps in an effort to evidence and regain and maintain compliance with the Bid Price Requirement.

Industry Context

StockSavvy.ai notes that maintaining listing on major exchanges like Nasdaq is critical for biotechnology and pharmaceutical companies, especially those in clinical development, as it directly impacts access to capital markets essential for funding research and development. Delisting can severely hinder a company's ability to raise funds and can erode investor confidence.

Stakeholder Impact

• Shareholders: Potential for continued stock price volatility and risk of delisting, which could lead to a material reduction in share value and liquidity.
• Investors: May experience a loss of confidence, impacting the ability to attract new investment.
• Employees: Potential impact on morale and retention if delisting occurs.
• Creditors/Suppliers: Delisting could affect the company's financial stability and ability to meet obligations.

Next Steps

• Demonstrate compliance with the $1.00 Minimum Bid Price Requirement by July 29, 2026.
• Maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026.
• Provide prompt notification to the Nasdaq Hearings Panel of any significant events affecting compliance.
• Continue to monitor the closing bid price and take steps to maintain compliance.

Key Dates

Recommendation

The company has secured a temporary reprieve from delisting, but the conditions are stringent and the outcome remains uncertain. The recent reverse stock split has not guaranteed compliance. Investors should hold their position while monitoring the company's ability to meet the bid price requirement through December 7, 2026, and await further developments before considering a buy or sell decision.

Keywords

Nasdaq Listing, Bid Price Requirement, Delisting, Reverse Stock Split, Genprex, Nasdaq Capital Market, Compliance